Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Moyi Wang
Institution:
Roswell Park Comprehensive Cancer Center
Observed institution:
Roswell Park Comprehensive Cancer Center
ORCID:
0000-0002-8227-6945
Observed ORCID:
0000-0002-8227-6945
OpenAlex ID:
A5090988218
Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises
2024
·
Wen (Jess) Li
, Yunfei Wang
, et al.
·
International Journal of Molecular Sciences
·
35
PDF
Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair
2021
·
Justin Zonneville
, Moyi Wang
, et al.
·
Communications Biology
·
13
PDF
Abstract 483: Organoids-based high-throughput drug screening identifies selective vulnerability of AR-/lo CRPC to inhibitors of neurotransmission signaling.
2026
·
Shan Wu
, Ruize Zhao
, et al.
·
Cancer Research
Abstract 2601: Lrig1 is a haplo-insufficient tumor suppressor and Lrig1-expressing cells can function as cells-of-origin of tumor development
2023
·
Moyi Wang
, Qiuhui Li
, et al.
·
Cancer Research
Abstract P1-16-07: A synthetic lethality treatment strategy for p53 mutant breast cancer
2022
·
Andrei Bakin
, Justin Zonneville
, et al.
·
Cancer Research
Abstract 1180: A novel synthetic lethality treatment strategy for metastatic breast cancer
2021
·
Justin Zonneville
, Moyi Wang
, et al.
·
Cancer Research
Show more works
View as search
Works count:
6
Citation count:
48
H-index:
2
I10-index:
2
Year
Topic
Type